Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol

1977 ◽  
Vol 11 (4) ◽  
pp. 239-245 ◽  
Author(s):  
B. -G. Hansson ◽  
J. -F. Dymling ◽  
H. Hedeland ◽  
U. L. Hulth�n
Keyword(s):  
Moderate Hypertension ◽  
Blocking Agent ◽  
Term Treatment ◽  
Receptor Blocking ◽  
Long Term Treatment

Short- and long-term treatment of mild to moderate hypertension with verapamil

1986 ◽  
Vol 57 (7) ◽  
pp. D83-D86 ◽  
Author(s):  
Pierre Wicker ◽  
Raymond Roudaut ◽  
Philippe Gosse ◽  
Modeste Dallocchio
Keyword(s):  
Moderate Hypertension ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Short And Long Term

Long-Term Treatment of Angina Pectoris with Carteolol: A New Beta-Adrenergic Receptor Blocking Agent

1986 ◽  
Vol 14 (4) ◽  
pp. 167-174 ◽  
Author(s):  
Robert R Luther ◽  
Harriet N Glassman ◽  
David C Jordan ◽  
Michael J Klepper ◽  
Keyword(s):  
Heart Rate ◽  
Angina Pectoris ◽  
Treatment Phase ◽  
Blocking Agent ◽  
Term Treatment ◽  
Double Product ◽  
Long Term Treatment ◽  
Exercise Induced ◽  
One Year

Seventy-two patients entered the treatment phase of an open, long-term, dose-ranging trial of carteolol in stable, exercise-induced angina pectoris. Patients were to be treated with progressive doses of carteolol (2.5, 5, 10, 20, 40, and 60 mg), given as a single daily oral dose. Thirty of the patients (42%) completed one year of treatment with carteolol as the sole antianginal therapy. The most frequent final carteolol doses were 20 mg and 40 mg once daily. Statistically significant improvements from baseline in exercise tolerance as reflected in time to onset of angina, time to the endpoint of exercise and time to the onset of 1 mm S-T segment change on ECG were observed in carteolol-treated patients. Exercise-induced increases in heart rate and double-product were significantly suppressed, compared to baseline, throughout the study. Resting heart rate and double-product were modestly decreased. Carteolol was shown to be effective and safe when administered on a long-term basis to patients with angina pectoris.

The Effect of Practolol (‘Eraldin’) in the Long-Term Treatment of Severe and Moderate Hypertension

1973 ◽  
Vol 45 (s1) ◽  
pp. 167s-170s ◽  
Author(s):  
R. M. Fulton ◽  
E. Hilda Fulton ◽  
K. G. Green
Keyword(s):  
Moderate Hypertension ◽  
Severe Hypertension ◽  
Term Treatment ◽  
Blood Levels ◽  
Safety Factors ◽  
First Choice ◽  
Long Term Treatment ◽  
Additional Safety

1. The results of a clinical trial of practolol in sixty-one patients with moderate and severe hypertension are presented. Alone or with a diuretic the drug was highly effective in thirty patients, and in a further eight who developed side effects. Effectiveness was not directly related to dosage or blood levels of drug, or to the severity of the hypertension. 2. Nine non-responders to practolol were found to respond to propranolol which is probably a more widely effective antihypertensive agent. Nevertheless, the additional safety factors of practolol and twice daily dosing make it first choice for many patients. We have been impressed by the ability of both β-blocking drugs to control blood pressure without impairing the quality of every-day life.

Sign in / Sign up

Export Citation Format

Share Document